PhoenixBio Co (TSE:6190) ROCE %: 13.42% (As of Mar. 2026)


TSE:6190 PhoenixBio Co Ltd TSE:6190
62 GF Score
Price 円324.00
GF Value 円361.16
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is PhoenixBio Co ROCE %?

PhoenixBio Co TSE:6190 -7.16% 62 ROCE % is 13.42% as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 62/100 and a GF Value™ of 円361.16 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PhoenixBio Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.42%.

PhoenixBio Co  (TSE:6190) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PhoenixBio Co ROCE % Related Terms

PhoenixBio Co ROCE % Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co ROCE % Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.80 28.75 3.12 -21.31 7.70

PhoenixBio Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -10.98 -31.98 2.21 13.42
TSE:6190
62GF Score
PhoenixBio Co Ltd TSE:6190
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhoenixBio Co ROCE % Calculation

PhoenixBio Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=136.237/( ( (2285.342 - 566.623) + (2192.682 - 373.299) )/ 2 )
=136.237/( (1718.719+1819.383)/ 2 )
=136.237/1769.051
=7.70 %

PhoenixBio Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=234.948/( ( (2101.006 - 419.519) + (2192.682 - 373.299) )/ 2 )
=234.948/( ( 1681.487 + 1819.383 )/ 2 )
=234.948/1750.435
=13.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.42% mean?
PhoenixBio Co (TSE:6190) has a ROCE % of 13.42% as of Mar. 2026.
Is PhoenixBio Co's ROCE % too high?
PhoenixBio Co's current ROCE % is 13.42%. Overall, PhoenixBio Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's ROCE % compare to VRTX and REGN?
PhoenixBio Co's ROCE % of 13.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. PhoenixBio Co's current ROCE % is 13.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Modestly Undervalued. The stock's GF Value™ is 円361.16, compared to a current price of 円324.00 — trading 10.3% below its estimated fair value. The current ROCE % is 13.42%. PhoenixBio Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current ROCE % is 13.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円324.00 is trading 10.3% below its estimated GF Value™ of 円361.16. GuruFocus considers PhoenixBio Co to be Modestly Undervalued.

Key valuation signals for TSE:6190:

  • ROCE %: 13.42%
  • GF Value™: 円361.16 vs. price of 円324.00 (10.3% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
62GF Score

Get the complete analysis for TSE:6190

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円324.00
Price
円361.16
GF Value